Welcome to our dedicated page for Cassava Sciences news (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences stock.
Cassava Sciences, Inc. (SAVA) is a clinical-stage biotechnology company pioneering Alzheimer's disease research through therapeutic candidate simufilam and diagnostic tool SavaDx. This page aggregates official press releases, regulatory updates, and material event announcements directly from the company and verified sources.
Investors and researchers will find timely updates on Phase 3 clinical trial progress, FDA communications, intellectual property developments, and peer-reviewed study publications. Our curated feed ensures access to SAVA's critical milestones in drug development and diagnostic innovation without promotional commentary.
Key content categories include clinical trial results, partnership announcements with research institutions, financial disclosures related to R&D funding, and scientific presentations at major medical conferences. All materials are organized chronologically to track the company's evolving research narrative.
Bookmark this page for streamlined monitoring of Cassava Sciences' advancements in Alzheimer's therapeutics. For comprehensive analysis, cross-reference updates with SEC filings and scientific publications linked in source materials.
Cassava Sciences, focused on Alzheimer’s disease, announced that Remi Barbier, President & CEO, will present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York on May 2nd at 3 PM Eastern time. This event provides a platform for the company to engage with institutional investors through one-on-one meetings. Investors can access the live webcast here and the archived replay here. Cassava Sciences aims to innovate treatments for neurodegenerative diseases by stabilizing key brain proteins, although none of their products have been approved by regulatory authorities.
Cassava Sciences (SAVA) announced its financial results for the year ending December 31, 2022, highlighting a cash balance of $201 million, down from $233.4 million in 2021. The company is focused on Alzheimer’s disease, with over 1,000 patients enrolled in Phase 3 studies of Simufilam. By year-end 2023, Cassava aims to enroll 1,750 patients. In Q2 2023, patient dosing for the Cognition Maintenance Study will be completed, with results expected in Q3 2023. The company reported a significant increase in R&D expenses to $68 million due to clinical study costs, while G&A expenses rose to $12 million.
On February 8, 2023, Cassava Sciences announced significant progress in its Phase 3 studies of simufilam, an oral drug for Alzheimer’s disease. A total of 953 patients are now enrolled across two studies, surpassing the halfway mark towards a combined target of approximately 1,750 patients. The company aims to complete enrollment by the end of 2023. Both studies have received FDA's Special Protocol Assessment and focus on evaluating the drug's safety and efficacy using established cognitive and functional scales. The CEO expressed optimism about meeting enrollment targets based on current trends.
Cassava Sciences (SAVA) announced positive top-line results from a Phase 2 study of simufilam, an oral treatment for Alzheimer’s disease. Over 200 patients with mild-to-moderate Alzheimer’s were treated for a year. Key findings include:
- 47% of participants improved on the ADAS-Cog scale, with an average improvement of 4.7 points.
- 23% showed minimal decline (less than 5 points).
- Simufilam was well tolerated, with no serious adverse events reported.
Patients in the mild group fared better with improvements in cognitive scores, while moderate patients experienced worsening. The company is preparing for Phase 3 trials in 2023.
FAQ
What is the current stock price of Cassava Sciences (SAVA)?
What is the market cap of Cassava Sciences (SAVA)?
